PATHOQUEST
23.1.2020 14:02:09 CET | Business Wire | Press release
PathoQuest, a company with expertise in genomic analysis, announced today that it has received GLP certificate of conformity following a successful inspection by the French National Agency for Medicine and Health Products Safety (ANSM). PathoQuest is the first company in France to have a facility receive such a GLP certificate from the ANSM for advanced, Next Generation Sequencing viral safety testing (“high-throughput sequencing detection of incidental replicative virus test in eukaryote cells ”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005345/en/
Violaine Melen, PathoQuest’s Chief of Quality Assurance and Regulatory Affairs, stated “we are really proud of the achievement of this key regulatory milestone. Receiving this GLP certificate is the confirmation of the quality of our entire process, from receipt of a biological sample to report generation, inclusive of bioinformatics analysis and data archiving. Our processes have been validated in accordance with highly recognized validation methods and computer systems guidelines such as ICHQ2(R1), IEC 62304, 21 CRF part 11, OECD annex 17.”
Next generation sequencing-based technology for biologics testing is intended to supplement or replace traditional in-vivo or in-vitro testing methods in order to support more rapid and robust decision-making as a part of the QC process. Jean-François Brepson, PathoQuest’s CEO, commented “Thanks to efficient teamwork, PathoQuest is now able to offer GLP-certified viral safety testing based on our proprietary NGS approach. This certification provides the company with a significant new market opportunity in addition to the current testing we perform in a R&D environment. Our innovative QC process is particularly adapted to biotech and biopharma companies developing Advanced Therapy Medicinal Products (ATMPs), vaccines and other biologicals .”
About PathoQuest
PathoQuest offers biopharmaceutical companies a game changing Genomic approach to secure the biosafety of biological drugs like cell & gene therapy products, vaccines and recombinant. It allows to reduce time to market of innovative treatments.
PathoQuest’s technology combines a Next-Generation Sequencing (NGS) platform with a proprietary sample preparation processes completed by a proprietary pathogen genome sequence databases and automated analysis pipeline.
PathoQuest has signed in 2018 a strategic partnership with Charles River Lab (Boston, USA).
Based on its technological platform, PathoQuest has also developed a metagenomic test direct from blood (iDTECT®) to improve the diagnosis of Bloodstream infections and fight against Antimicrobial Resistance (AMR)
For more information about PathoQuest, visit www.pathoquest.com or contact us at welcome@pathoquest.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200123005345/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HyperLight Demonstrates Low-Power 1.6T-DR8 TFLN-based Reference Transceiver Assembled by TFC16.3.2026 13:03:00 CET | Press release
HyperLight Corporation (“HyperLight”) today announced a major milestone in low-power optical networking with the demonstration of a 1.6T-DR8 optical transceiver leveraging HyperLight’s TFLN Chiplet™ Platform. The reference module was demonstrated with engineering and manufacturing support from Suzhou TFC Optical Communication Co., Ltd. (SZSE: 300394, or "TFC"). The reference design achieves 20W power consumption in a fully retimed 1.6T-DR8 module, representing approximately 20% lower module-level power compared to alternative technologies. The reduction is achieved through a simple drop-in transmitter implementation based on a single thin-film lithium niobate photonic integrated circuit (TFLN PIC). The TFLN transmitter enables the module to operate using a single continuous-wave (CW) laser, compared to the two to four lasers typically required in conventional implementations. Additional energy savings are achieved through the ability to operate directly from the native low-swing electr
GCE® Launches Gascontrol.com Website Showcasing Its Complete Gas Control Portfolio for Speciality, Medical, and Industrial Applications16.3.2026 13:00:00 CET | Press release
GCE®, a global market leader for gas control equipment, has launched gascontrol.com, a new website designed to better serve customers across its GCE Specialty, GCE Medical, and GCE Industrial product portfolios. The new site provides a streamlined, market-focused experience that makes it easier for users to explore GCE’s gas control solutions and identify the right products. A new Documentation Search Tool assists customers in easily finding documents such as instructions for use (IFUs), appendices, and certifications through an intuitive search interface. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316410525/en/ GCE’s new website, gascontrol.com, provides a streamlined, market-focused experience across the GCE Specialty, GCE Medical, and GCE Industrial product portfolios. “The redesigned website reflects GCE’s role as a comprehensive, trusted supplier of gas control technologies that elevate industries and improve liv
SBC Medical Announces Opening of Brand Flagship "NEO Skin Clinic Ginza."16.3.2026 13:00:00 CET | Press release
Accelerating multi-branding strategy in aesthetic healthcare with global presence in Tokyo’s premier district SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced that its specialized aesthetic brand, “NEO Skin Clinic,” will open its flagship location in Tokyo’s Ginza district, a globally recognized medical tourism hub and highly competitive district, on Saturday, March 28, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312457783/en/ SBC Medical Announces Opening of Brand Flagship "NEO Skin Clinic Ginza." The Ginza flagship, located in a prime area near GINZA SIX, will feature dedicated VIP rooms for executive clientele and the growing number of international patients, strengthening the brand’s global presence. Leveraging its robust network of 283 affilia
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis16.3.2026 11:53:00 CET | Press release
Almirall announces positive, top-line results from Phase 3 ADorable-1 trialADorable-1 met co-primary efficacy endpoints, with 63% of paediatric patients achieving meaningful skin improvement (EASI-75) and 44% reaching clear or almost clear skin (IGA 0,1) at week 16.Key secondary endpoints showed significant itch relief (Pruritus NRS ≥4 point improvement), reduced overall disease severity (EASI-90) and improved quality of life (CDLQI ≥6-Point Improvement) in children and adolescents with moderate-to-severe atopic dermatitis treated with lebrikizumab.Skin conditions can have a profound physical and emotional impact on people’s lives1, and Atopic Dermatitis (AD) peaks in childhood – with around 60% of cases appearing within the first year of life2. Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and safety of lebrikizumab for children and adoles
Experian Marks a Breakthrough in Consumer AI with the Next Evolution of Its Virtual Assistant16.3.2026 11:00:00 CET | Press release
Smarter, more adaptive assistant advances personalized, conversational financial guidance powered by trusted data Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™, a significant advancement in its Consumer First AI strategy that expands personalized, conversational financial guidance to millions of consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316538160/en/ Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™. “This next generation of EVA reflects the direction of our consumer AI strategy,” said Debbie Hsu, Executive Vice President of Product, Experian Consumer Services. “We are bringing together conversational AI, personalization, and our trusted data foundation to deliver guidance that is intuitive, relevant, and actionable. Our focus is on helping consumers make smarter financial decisions in ways that feel simple and empowering.” Built to scal
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom